---
document_datetime: 2023-09-21 16:59:43
document_pages: 5
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/nespo-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
document_name: nespo-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 4.6382085
conversion_datetime: 2025-12-22 07:47:44.275853
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Nespo

| No      | Scope                                                                                                                                                                                                                                                                                                                        | Opinion issued on   | Commission Decision Issued/ amended on   | Product Information affected 2   | Summary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------|------------------------------------------|----------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0047 | Update of Summary of Product Characteristics and Package Leaflet                                                                                                                                                                                                                                                             | 25/09/2008          | 28/10/2008                               | SPC, PL                          | longer This variation primarily concerns an update of the SPC following the completion of a class safety review by the PhVWP and the CHMP. The safety review was initiated because recent data show a consistent unexplained excess mortality in cancer patients with anaemia treated with epoetins. As a result, CHMP requested to update section 4.4 of the SPC to include an additional ESA class warning in the epoetins with cancer indication. The Package Leaflet has been updated accordingly |
| II/0046 | Update of DDPS (Pharmacovigilance) Update of Detail Description of the Pharmacovigilance System (Pharmacovigilance)                                                                                                                                                                                                          | 25/09/2008          | product no 28/10/2008                    | Annex II                         | The Marketing Authorisation Holder applied to update the Detailed Description of the Pharmacovigilance System (DDPS). There have been no significant changes made to the MAH's pharmacovigilance systems. Version 3.0 of the DDPS has been updated in line with the summary of pharmacovigilance systems submitted in May 2008. The changes are administrative and provide further clarity on the pharmacovigilance systems in place.                                                                 |
| II/0045 | Update of Summary of Product Characteristics and Package Leaflet Update of sections 4.4 and 4.8 of the SPC following an update of the Company Core Data Sheet. The package leaflet has also been amended accordingly. The MAHalso introduced a Getting Started Guide (GSG) as additional information to the package leaflet. | 24/07/2008          | 29/08/2008                               | SPC, PL                          | Update of sections 4.4 and 4.8 of the SPC following an update of the Company Core Data Sheet. The package leaflet has also been amended accordingly. The MAHalso introduced a Getting Started Guide (GSG) as additional information to the package leaflet.                                                                                                                                                                                                                                           |

Medicinal product no longer authorised Procedural steps taken and scientific information after the authorisation Changes made after 01/09/2003 For procedures finalised before 01/09/2003, please refer to module 8A MAJOR CHANGES 1 1 Major changes e.g. Type II variations, Annex II applications, Renewals and Annual Reassessments 2 SPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet)

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

| No      | Scope                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Opinion issued on   | Commission Decision Issued/ amended on   | Product Information affected 2   | Summary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------|------------------------------------------|----------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| X/0043  | 01_vi_Qualitative change in declared active substance - Other                                                                                                                                                                                                                                                                                                                                                                                                            | 24/04/2008          | 03/07/2008                               | Annex II                         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| II/0044 | Update of Summary of Product Characteristics and Package Leaflet                                                                                                                                                                                                                                                                                                                                                                                                         | 24/01/2008          | 26/02/2008                               | no SPC, PL                       | longer authorised This variation primarily concerns an update of the SPC following the completion of a class safety review by the PhVWP and the CHMP. The safety review was initiated because recent data show a consistent unexplained excess mortality in cancer patients with anaemia treated with epoetins, and that treatment of anaemia with epoetins in patients with chronic kidney disease to achieve relatively high target haemoglobin concentrations may be associated with an increase in the risk of mortality and cardiovascular morbidity. As a result, the main changes being implemented are: i) in section 4.1, to highlight that epoetins should be used only if associated with symptoms, ii) in Section 4.2 to establish a uniform target haemoglobin range for all epoetins, iii) in Section 4.4 to mention the observed negative benefit risk balance in patients treated with high target haemoglobin concentrations, and iv) in section 5.1 to include the relevant results of the trials triggering the safety review. The package leaflet has also been updated accordingly. Additional sections 2, 4.9 and 5.2 have also been amended to correct minor inconsistencies. In addition, the MAHhas taken this opportunity to re-format the approved package leaflet and take into account the results of user testing. |
| II/0036 | Medicinal product Extension of Indication The MAHhas submitted an extension of indication to allow treatment to CRF paediatric subjects >/=11 years of age. As a result, sections 4.1, 4.2 and 5.2 of the SPC have been updated. New data from efficacy and safety based study 20000100 supports removing this restriction, and allow treatment of all ages of CRF paediatric subjects, in addition to adults. As a result of this, section 4.2 of the SPC has also been | 19/07/2007          | 30/08/2007                               | SPC, PL                          | Please refer to the Scientific Discussion: Nespo-H-333-II-36-AR.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |

<div style=\"page-break-after: always\"></div>

| No      | Scope                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Opinion issued on   | Commission Decision Issued/ amended on   | Product Information affected 2   | Summary                                                                                                                                                                                                                                                                               |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------|------------------------------------------|----------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|         | updated to provide clarity over dosing paediatric subjects. The data from pharmacokinetic (PK) study 20000126 investigated in paediatric subjects with nonmyeloid malignancies who were receiving chemotherapy supports an additional statement in section 5.2 of the SPC. The limited PK data in paediatric subjects receiving chemotherapy is only supportive of a statement in section 5.2 of the SPC, with regards to the study findings. The package leaflet was updated accordingly. |                     |                                          |                                  | longer authorised                                                                                                                                                                                                                                                                     |
| II/0040 | New presentation(s)                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 22/03/2007          | 02/05/2007                               | SPC, Labelling, PL               |                                                                                                                                                                                                                                                                                       |
| II/0041 | Change(s) to the manufacturing process for the finished product                                                                                                                                                                                                                                                                                                                                                                                                                            | 22/03/2007          | 28/03/2007                               |                                  |                                                                                                                                                                                                                                                                                       |
| II/0039 | Update of Summary of Product Characteristics and Package Leaflet                                                                                                                                                                                                                                                                                                                                                                                                                           | 18/10/2006          | product no 28/11/2006                    | SPC, PL                          | To amend sections 4.2 and 5.1 of the SPC in response to CHMP request (FUM 056) requiring the MAHto remove the recommendation for dose increase in patients receiving darbepoetin alfa once weekly with an inadequate response. The Package Leaflet has been amended accordingly.      |
| II/0038 | Update of Summary of Product Characteristics                                                                                                                                                                                                                                                                                                                                                                                                                                               | 21/09/2006          | 30/10/2006                               | SPC                              | The MAHhas applied to amend section 5.1 of the SPC to modify the language relating to influence of darbepoetin alfa on tumour progression and survival for lymphoproliferative subjects treated with darbepoetin alfa.                                                                |
| II/0035 | Change(s) to the manufacturing process for the active substance                                                                                                                                                                                                                                                                                                                                                                                                                            | 27/07/2006          | 03/08/2006                               |                                  |                                                                                                                                                                                                                                                                                       |
| R/0034  | Renewal of the marketing authorisation                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 23/03/2006          | 19/05/2006                               | SPC, Labelling, PL               |                                                                                                                                                                                                                                                                                       |
| II/0033 | Update of or change(s) to the pharmaceutical documentation                                                                                                                                                                                                                                                                                                                                                                                                                                 | 23/02/2006          | 28/02/2006                               |                                  |                                                                                                                                                                                                                                                                                       |
| II/0032 | Medicinal Update of Summary of Product Characteristics and Package Leaflet                                                                                                                                                                                                                                                                                                                                                                                                                 | 26/01/2006          | 28/02/2006                               | SPC, PL                          | The MAHhas applied to amend sections 4.2 and 5.2 to modify the posology for patients with chronic renal failure switching from recombinant human erythropoietin to darbepoetin alfa during the maintenance phase of treatment. The Package Leaflet has also been amended accordingly. |

<div style=\"page-break-after: always\"></div>

| No      | Scope                                                                                                                             | Opinion issued on   | Commission Decision Issued/ amended on   | Product Information affected 2   | Summary                                                                                                                                                                                                                                                                                                                                                              |
|---------|-----------------------------------------------------------------------------------------------------------------------------------|---------------------|------------------------------------------|----------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0031 | Update of Summary of Product Characteristics and Package Leaflet                                                                  | 27/07/2005          | 08/09/2005                               | SPC, PL                          | authorised The MAHhas applied to update sections 4.4 and 4.8 of the SPC in relation to Pure Red Cell Aplasia. The Package Leaflet has also been updated accordingly.                                                                                                                                                                                                 |
| II/0030 | Change(s) to the manufacturing process for the active substance                                                                   | 27/07/2005          | 03/08/2005                               |                                  |                                                                                                                                                                                                                                                                                                                                                                      |
| II/0029 | Update of Summary of Product Characteristics and Package Leaflet                                                                  | 26/05/2005          | 08/07/2005                               | SPC, PL                          | Please refer to the Scientific Discussion: Nespo-H-333-II-29                                                                                                                                                                                                                                                                                                         |
| II/0028 | Quality changes The Marketing Authorisation Holder applied to change the product specifications.                                  | 16/03/2005          | 23/03/2005                               |                                  | longer                                                                                                                                                                                                                                                                                                                                                               |
| II/0027 | New presentation(s) The Marketing Authorisation Holder applied to add a new pre-filled pen injection device to the product range. | 20/01/2005          | 28/02/2005                               | no SPC, Labelling, PL            |                                                                                                                                                                                                                                                                                                                                                                      |
| II/0025 | Update of Summary of Product Characteristics and Package Leaflet                                                                  | 29/07/2004          | 09/09/2004                               | SPC, PL                          | The marketing authorisation holder applied to support the extension of the dosing intervals in the treatment of anaemia associated with chronic renal failure in adults and paediatric subjects 3 11 years of age (once monthly) and in adults with chemotherapy-induced anaemia (once every three week). The SPC and Package Leaflet have been updated accordingly. |
| II/0023 | product Update of Summary of Product Characteristics and Package Leaflet                                                          | 26/02/2004          | 14/04/2004                               | SPC, PL                          | The marketing authorisation holder applied to introduce additional text to Section 4.4 \"Special Warnings and Special Precautions for Use\" and Section 4.8 \"Undesirable Effects\" of the SPC. The package leaflet has been updated accordingly.                                                                                                                        |
| II/0022 | Update of Summary of Product Characteristics and Package Leaflet                                                                  | 21/01/2004          | 21/01/2004                               | SPC, PL                          |                                                                                                                                                                                                                                                                                                                                                                      |

<div style=\"page-break-after: always\"></div>

| No      | Scope                                                                                                                                                                          | Product Information affected 2   | Date 4     |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|------------|
| N/0042  | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                               | PL                               | 31/07/2007 |
| IB/0037 | 41_a_02_Change in pack size - change in no. of units outside range of appr. pack size IB_41_a_02_Change in pack size - change in no. of units outside range of appr. pack size | SPC, Labelling, PL               | 31/07/2006 |
| IA/0026 | 28_Change in any part of primary packaging material not in contact with finished product 41_a_01_Change in pack size - change in no. of units within range of appr. pack size  | SPC, Labelling, PL               | 26/05/2004 |

<!-- image -->